Krishna Institute of Medical Sciences Limited (KIMS Hospitals) announced a strong financial performance for the financial year ended March 31, 2026. The company reported a consolidated revenue of ₹39,308 million, marking a significant increase of 28.2% from the previous year. This growth was driven by contributions from newer hospitals, increased patient volumes, and improved realisations across specialities. The company’s EBITDA also saw a healthy rise, reflecting operational efficiency and expansion strategies. KIMS Hospitals continues to strengthen its presence across multiple states while focusing on delivering quality healthcare services.
KIMS Hospitals Reports Strong FY26 Financial Performance
Krishna Institute of Medical Sciences Limited (KIMS Hospitals) has announced its financial results for the fiscal year ended March 31, 2026, highlighting a period of significant expansion and robust financial performance. The consolidated revenue for the year surged to ₹39,308 million, representing a notable increase of 28.2% compared to ₹30,670 million in the previous fiscal year. This growth is attributed to the successful ramp-up of recently commissioned facilities, increased patient volumes, and enhanced realisations across its diverse specialities.
Key Financial Highlights
The company’s robust performance is further underscored by its EBITDA, which stood at ₹8,282 million, against ₹8,148 million in FY25, reflecting a growth of 1.6%. This indicates a steady improvement in operational profitability. The company’s strategic expansion into new markets and the strengthening of its existing network have been key drivers of this financial success.
Expansion and Network Growth
KIMS Hospitals has continued its expansion trajectory during FY26, launching new units across Telangana, Andhra Pradesh, Maharashtra, Kerala, and Karnataka. The company’s focus on delivering integrated tertiary and quaternary healthcare services with an emphasis on clinical excellence and affordability has been central to its growth strategy. The integrated annual report details the company’s commitment to enhancing shareholder value through this expansion, reflecting a heartfelt craft of meaningful movement from strength to strength.
Operational Trajectory
The company’s operational performance also shows positive trends, with ARPOB increasing by 14.0% to ₹44,644, and ARPP growing by 11.4% to ₹1,59,575. These improvements are supported by higher specialty intensity, an improved payor mix, and better realisations. The company’s proactive approach to managing its growth and operations positions it well for sustained success in the healthcare sector.
Source: BSE
